Drug
Bimekizumab
Bimekizumab: highest development phase Phase 3, developed by UCB. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- UCB
Trials
| Drug | Phase | Indication |
|---|---|---|
| Bimekizumab NCT04436640 | Phase 3 | Axial Spondyloarthritis |
| Bimekizumab NCT04242446 | Phase 3 | Hidradenitis Suppurativa |
| Bimekizumab NCT06668181 | Phase 3 | Enthesitis-related Arthritis |
| Bimekizumab NCT04242498 | Phase 3 | Hidradenitis Suppurativa |
Latest
No recent events.
Follow Bimekizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.